

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313 1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/688,572	10/17/2003	Xiaoli Chen	PRD-50-NP	2487
27777 7 :	590 10/25/2004		EXAMINER	
PHILIP S. JOHNSON			REYES, HECTOR M	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			ART UNIT	PAPER NUMBER
			1625	
			DATE MAILED: 10/25/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/688,572	CHEN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Hector M Reyes	1625			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 19 A	<u>pril 2004</u> .				
2a) This action is FINAL . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-42 is/are pending in the application. 4a) Of the above claim(s) is/are withdray. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-42 are subject to restriction and/or of the specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11)	wn from consideration. election requirement. er. epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document * See the attached detailed Office action for a list 	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage			
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D				
Notice of Draitsperson's Patent Drawing Review (P10-940) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	a. 🗀	Patent Application (PTO-152)			

Art Unit: 1625

Restriction to one of the following inventions is required under 35 U.S.C. 121: ELECTION RESTRICTION REQUEST

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claims 1-32 in part, drawn to <u>HETEROCYCLIC</u> compounds, pharmaceutical acceptable salts thereof, C₁₋₆ ester and amide derivatives thereof and pharmaceutical compositions comprising the same, classified in multiple classes and multiple subclasses. This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.
- II. Claims 1-32 in part, drawn to **NON HETEROCYCLIC** compounds, pharmaceutical acceptable salts thereof, C₁₋₆ ester and amide derivatives thereof and pharmaceutical compositions comprising the same, classified in multiple classes and multiple subclasses. **This group may be** subjected to further restriction. *A single disclosed species is hereby requested for search purpose.*
- Claims 33-42 in part, drawn to multiple methods using to pharmaceutical compositions comprising HETEROCYCLIC compounds or derivatives thereof classified in multiple classes and multiple subclasses. This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.

Art Unit: 1625

IV. Claims 33-42 in part, drawn to multiple methods using to pharmaceutical compositions comprising <u>NON HETEROCYCLIC</u> compounds or derivatives thereof classified in multiple classes and multiple subclasses.
This group may be subjected to further restriction. A single disclosed species is hereby requested for search purpose.

The inventions are distinct, each from the other because of the following reasons: Inventions II and I are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because each set of compounds embraced by each particular Group does not have the same substantial core. Moreover, each set of compounds embraced by each group has a different structure and reactivity from the others that a reference anticipating one group would not necessarily render the other obvious and to search all the different structurally diverse compounds in a single application would present a serious undue burden to the Examiner.

Inventions I-II AND III-IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of

Art Unit: 1625

using that product (MPEP § 806.05(h)). In the instant case it is well known that the prior art teaches alternatives treatments for the diseases embraced in the instant claims. For instance there are multiple methods for treating hypertension which do not require at all the compounds described in the instant application. On the other hand, the said products can be use in synthetic procedure to prepare more complex organic targets.

Groups III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because compounds required in the methods of treatment as described in Group III are not required for the methods of treatment of Group IV, therefore each invention is capable of use independently from the other.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for a given Group is not required for any other Group, restriction for examination purposes as indicated is proper.

1// 00/1/10/ 144///2011 10/000,

Art Unit: 1625

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete <u>must include an</u>

<u>election of the invention to be examined even though the requirement be</u>

<u>traversed</u> (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

In the event that Applicant's election is directed to a group drawn to compounds salts and compositions thereof, and if the said compounds, salts and compositions are found allowable, the Examiner is kindly willing to rejoin methods of using the said particular compounds limited to the scope of the allowable compounds and provided that claims describing the said methods of using are free form any 35 USC 112 issues.

Art Unit: 1625

CONCLUSION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hector M Reyes whose telephone number is (571) 272-0691. The examiner can normally be reached on M-F (9:00 AM-5:30 PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, Rita Desai can be reached on (571) 272-0684. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). 10/21/04

Hector M. Reyes PhD JD Reg # P-54, 846 Au 1625 October 21, 2004 Application/Control Number: 10/688,572 Page 7

Art Unit: 1625